- Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586
-
SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). Different strategies have been studied to synthesize this molecule and among the strategies an
- Metro, Thomas-Xavier,Cochi, Anne,Gomez Pardo, Domingo,Cossy, Janine
-
scheme or table
p. 2594 - 2602
(2011/06/20)
-
- SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
-
A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and
- -
-
Page/Page column 11
(2011/08/04)
-
- Enantioselective synthesis of SSR 241586 by using an organo-catalyzed Henry reaction
-
An organo-catalyzed Henry reaction, applied to an α-keto ester, has allowed the enantioselective synthesis of SSR 241586, a 2,2-disubstituted morpholine active in the treatment of schizophrenia and irritable bowel syndrome (IBS).
- Cochi, Anne,Metro, Thomas-Xavier,Pardo, Domingo Gomez,Cossy, Janine
-
supporting information; experimental part
p. 3693 - 3695
(2010/10/20)
-
- SULFUR CONTAINING PYRAZOLE-HETEROCYCLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
-
A novel sulfur containing heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-re
- -
-
Page/Page column 28
(2010/04/27)
-
- FUNGICIDAL PYRIDAZINES
-
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, R4, X, Y and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
- -
-
Page/Page column 51
(2010/04/27)
-